Tests and monitoring tools
Articles tagged with Therapeutic Drug Monitoring in the tests and monitoring topic, grouped for easier browsing of related monitoring, diagnosis, and research updates.
13 articles
Biomarker discordance is common in treat-to-target IBD care; understanding which tests reflect local gut inflammation versus systemic response can help avoid unnecessary treatment changes and guide targeted...
Using TDM to optimize vedolizumab could improve outcomes but may raise treatment costs; patients and clinicians should know cost-effectiveness depends heavily on drug price and local healthcare thresholds.
Reliable, high-throughput lab methods are a prerequisite for therapeutic drug monitoring (TDM). For people with IBD on JAK inhibitors, validated assays can enable exposure measurement needed for future precision dosing...
Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.
People with Crohn’s disease on ustekinumab may be more likely to need intensified dosing if they previously tried biologics or immunomodulators or have had disease longer; this could affect monitoring and planning. For...
Faster remission can reduce symptoms, school disruption, and steroid exposure for children with IBD. If earlier infliximab level checks reliably speed remission, clinicians could adjust dosing sooner to improve outcomes.
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...
Vedolizumab blood levels can vary with disease activity; a model that links intestinal α4β7 expression to drug exposure helps explain why some patients have lower drug levels and may need different dosing. This could...
The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...
Infliximab dosing can be hard to personalize. This study shows that selecting pharmacokinetic models based on IBD type and severity can improve how well drug levels are predicted, which could help tailor dosing for...
Reactive TDM can help determine why a child with Crohn's disease is losing response to adalimumab and guide whether to escalate dose or switch biologics, which affects short-term management decisions.
Proactive TDM of infliximab was associated with high 1‑ and 2‑year durability in this pediatric Crohn's cohort, and the study flags clinical factors that may predict need to switch biologics. This could be relevant when...
A coordinated national research network can accelerate studies that matter to people with IBD—like tracking real-world disease patterns, testing diet and psychosocial approaches, improving monitoring with biomarkers and...
